M.D. Anderson Cancer Center
The purpose of this research study is learn about the effects of Thyroid GuidePx® on papillary thyroid cancer treatment recommendations when the test result is disclosed after surgery.
Primary Objectives: To determine the decision impact of Thyroid GuidePx® when results are disclosed postoperatively, defined across three prespecified decision domains: 1. Extent of initial surgery (counterfactual): (i) among patients who actually had a total thyroidectomy, through the post-test clinician survey, whether Thyroid GuidePx® results would have changed surgical extent and lobectomy would have been appropriate. This includes patients who underwent intraoperative conversion from lobectomy to total thyroidectomy due to gross extrathyroidal extension or unexpected central nodal metas…
Inclusion Criteria: disease who can potentially be treated with lobectomy will be recruited to the study. Lobectomy-candidate status is determined by the treating physician using standard institutional criteria (e.g., tumor 1-4 cm, cN0/Nx, no gross ETE). Patients may still undergo total thyroidectomy as part of shared decision-making. Inclusion criteria: * Patients aged 18 years or older at the time of enrollment * English-speaking * Bethesda V or VI cytology following FNA of a thyroid nodule (papillary thyroid cancer) * Preoperative candidacy for lobectomy * Tumor 1 - 4 cm in size * N…
Participants will be offered enrollment in this study, in which Thyroid GuidePx® will be performed on an intraoperative FNA (ioFNA) collected during surgery, with results disclosed postoperatively.
Arctuva estimate
Actual pay is set by the research site.
Verify or correct the compensation shown for this listing.